129 related articles for article (PubMed ID: 38678323)
21. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
[TBL] [Abstract][Full Text] [Related]
23. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
[TBL] [Abstract][Full Text] [Related]
24. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Illei PB; Rusch VW; Zakowski MF; Ladanyi M
Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
[TBL] [Abstract][Full Text] [Related]
26. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
[TBL] [Abstract][Full Text] [Related]
27. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
Krasinskas AM; Bartlett DL; Cieply K; Dacic S
Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
[TBL] [Abstract][Full Text] [Related]
29. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.
Vij M; Cho BB; Yokoda RT; Rashidipour O; Umphlett M; Richardson TE; Tsankova NM
Acta Neuropathol Commun; 2023 May; 11(1):73. PubMed ID: 37138345
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
31. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
[TBL] [Abstract][Full Text] [Related]
32. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
[TBL] [Abstract][Full Text] [Related]
33. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
[TBL] [Abstract][Full Text] [Related]
36. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
37. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
[TBL] [Abstract][Full Text] [Related]
38. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
39. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
[TBL] [Abstract][Full Text] [Related]
40. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
